Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrixtamig + Platinum/Etoposide in Advanced LCNEC
NCT07561645Phase 2Not yet recruiting
- Sponsor
- Technische Universität Dresden
- Start
- Sep 2026
- Primary completion
- Apr 2032
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
01
Overview
A Phase 2 trial of obrixtamig in large cell neuroendocrine carcinoma of the lung (LCNEC), sponsored by Technische Universität Dresden. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
obrixtamig
03
Conditions
large cell neuroendocrine carcinoma of the lung (LCNEC)
Beyond the preview
Go deeper on NCT07561645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07561645.